Skip to main content
SpringerLink
Log in
Book cover

Multiple Myeloma pp 273–284Cite as

Allogeneic Transplantation in Multiple Myeloma

  • Chapter
  • First Online:

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 183))

Abstract

Allogeneic hematopoietic stem cell transplantation in multiple myeloma has been performed since the 1980th, but is still a controversial treatment modality. The aim is to cure the disease and the rational is to eradicate myeloma cells by the dual effect of high dose myeloablative treatment, and the immune reaction against the myeloma cells by the graft (graft versus myeloma =GVM). At the same time the patient is saved from myeloablation by the normal allogeneic donor stem cells. Although outcome has improved with time the transplant related mortality using myeloablation is still high. Therefore reduced intensity non-myelablative conditioning (RIC) has increasingly substituted myeloablation and results have improved. Out of five published or ongoing prospective clinical trials using tandem autologous (ASCT) – RIC-allogeneic transplantation (RIC-allo) compared to tandem or single ASCT the tandem ASCT-RIC-Allo approach was superior. Attempts to improve outcome by adding new drugs ( thalidomide, bortezomib or lenalidomide ) or alternative cell therapies like donor T-cell infusions or NK cell treatment may improve results.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Alici E, Konstantinidis KV, Sutlu T, Aints A, Gahrton G, Ljunggren HG, Dilber MS (2007) Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Exp Hematol 35:1839–1846

    Article  PubMed  CAS  Google Scholar 

  • Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, Quezada HC, Gahrton G, Ljunggren HG, Dilber MS (2008) Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 111:3155–3162

    Article  PubMed  CAS  Google Scholar 

  • Ayuk F, Perez-Simon JA, Shimoni A, Sureda A, Zabelina T, Schwerdtfeger R, Martino R, Sayer HG, Alegre A, Lahuerta JJ, Atanackovic D, Wolschke C, Nagler A, Zander AR, San Miguel JF, Kroger N (2008) Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica 93:1343–1350

    Article  PubMed  Google Scholar 

  • Bjorkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, Blade J, Carlson K, Cavo M, Ferrant A, Goldstone AH, de Laurenzi A, Majolino I, Marcus R, Prentice HG, Remes K, Samson D, Sureda A, Verdonck LF, Volin L, Gahrton G (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88:4711–4718

    PubMed  CAS  Google Scholar 

  • Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone P, Corradini P, Goldschmidt H, De Witte T, Morris C, Niederwieser D, Gahrton G (2008) Autologous stem cell transplantation (ASCT) versus ASCT followed by redued- intensity conditioning allogeneic SCT with identical sibling donor in previously untreated multiple myeloma: prelliminary analysis of a prospective controlled trial by the EBMT. Bone Marrow Transplant 41:S38

    Google Scholar 

  • Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, Giaccone L, Sorasio R, Omede P, Baldi I, Bringhen S, Massaia M, Aglietta M, Levis A, Gallamini A, Fanin R, Palumbo A, Storb R, Ciccone G, Boccadoro M (2007) A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356:1110–1120

    Article  PubMed  CAS  Google Scholar 

  • Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A, Van Lint MT, Bacigalupo A, Santoro A, Musso M, Majolino I, Boccadoro M, Pileri A (1999) Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 17:208–215

    PubMed  CAS  Google Scholar 

  • Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A, Russell N, Montefusco V, Voena C, Gahrton G (2003) Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 102:1927–1929

    Article  PubMed  CAS  Google Scholar 

  • Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G (2007) Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 109:3588–3594

    Article  PubMed  CAS  Google Scholar 

  • Gahrton G, Bjorkstrand B (2008) Allogeneic transplantation in multiple myeloma. Haematologica 93:1295–1300

    Article  PubMed  CAS  Google Scholar 

  • Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, Facon T, Granena A, Gore M, Gratwohl A et al (1991) Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 325:1267–1273

    Article  PubMed  CAS  Google Scholar 

  • Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B, Blade J, Cornelissen J, de Laurenzi A, Facon T, Ljungman P, Michallet M, Niederwieser D, Powles R, Reiffers J, Russell NH, Samson D, Schaefer UW, Schattenberg A, Tura S, Verdonck LF, Vernant JP, Willemze R, Volin L (2001) Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 113:209–216

    Article  PubMed  CAS  Google Scholar 

  • Gahrton G, Iacobelli S, Apperley J, Bandini G, Bjorkstrand B, Blade J, Boiron JM, Cavo M, Cornelissen J, Corradini P, Kroger N, Ljungman P, Michallet M, Russell NH, Samson D, Schattenberg A, Sirohi B, Verdonck LF, Volin L, Zander A, Niederwieser D (2005) The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant 35:609–617

    Article  PubMed  CAS  Google Scholar 

  • Gahrton G, Iacobelli S, Bandini G, Bjorkstrand B, Corradini P, Crawley C, Hegenbart U, Morgan G, Kroger N, Schattenberg A, Schonland SO, Verdonck LF, Volin L, de Witte T, Niederwieser D (2007) Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica 92:1513–1518

    Article  PubMed  Google Scholar 

  • Gahrton G, Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D (2009) Tandem autologous(ASCT)/ allogeneic reduced intensity conditioning transplantation (RIC) with identical sibling donor versus ASCT in previously untreated multiple myeloma (MM): Long term follow up of a prospective controlled trial by the EBMT. Blood 114(abstr):52

    Google Scholar 

  • Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C, Dib M, Caillot D, Deprijck B, Ketterer N, Harousseau JL, Sotto JJ, Moreau P (2006) Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107:3474–3480

    Article  PubMed  CAS  Google Scholar 

  • Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML, Shizuru JA, Lange T, Agura ED, Bruno B, McSweeney PA, Pulsipher MA, Chauncey TR, Mielcarek M, Storer BE, Storb R (2007) Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Biol Blood Marrow Transplant 13:423–432

    Article  PubMed  CAS  Google Scholar 

  • Hambach L, Spierings E, Goulmy E (2007) Risk assessment in haematopoietic stem cell transplantation: minor histocompatibility antigens. Best Pract Res Clin Haematol 20:171–187

    Article  PubMed  CAS  Google Scholar 

  • Lokhorst H, Sonneveld P, van der Holt B, van Oers M, Raymakers R, Zweegman S, Minnema M, Zijlmans M (2008) Donor versus no donor analysis of newly diagnosed myeloma patients included in the HOVON 50/54 Study. Blood 112(abstr):461

    Google Scholar 

  • Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, Storer B, Hegenbart U, Somlo G, Chauncey T, Bruno B, Appelbaum FR, Blume KG, Forman SJ, McSweeney P, Storb R (2003) Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102:3447–3454

    Article  PubMed  CAS  Google Scholar 

  • Mattei D, Mordini N, Vigna Taglianti R, Bruno B, Rapezzi D, Gallamini A (2005) Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse. Haematologica 90:861–862

    PubMed  Google Scholar 

  • Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM (2008) Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4(+)Foxp3(+) T cells. Leukemia. 2009; 23:605–607

    Google Scholar 

  • Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C, Benboubker L, Doyen C, Mohty M, Yakoub-Agha I, Leyvraz S, Casassus P, Avet-Loiseau H, Garderet L, Mathiot C, Harousseau JL (2008) Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 112:3914–3915

    Article  PubMed  CAS  Google Scholar 

  • Remberger M, Mattsson J, Svahn B, Ringdén O (2008) Using reduced intensity conditioning and HLA-identcal sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose Bone Marrow Transplant. 2008; 42:769–771

    Google Scholar 

  • Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, Gonzalez JD, Diaz-Mediavilla J, Hernandez B, Garcia-Frade J, Carrera D, Leon A, Hernandez M, Fernandez Abellan P, Bergua JM, San Miguel J, Blade J (2008) A prospective pethema study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112(9):3591–3593

    Article  PubMed  CAS  Google Scholar 

  • Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097–2100

    Article  PubMed  CAS  Google Scholar 

  • Ruggeri L, Capanni M, Mancusi A, Martelli MF, Velardi A (2005) The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation. Transpl Immunol 14:203–206

    Article  PubMed  CAS  Google Scholar 

  • Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD Jr, Barlogie B, van Rhee F (2008) Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 143:641–653

    Article  PubMed  Google Scholar 

  • Sun K, Welniak LA, Panoskaltsis-Mortari A, O’Shaughnessy MJ, Liu H, Barao I, Riordan W, Sitcheran R, Wysocki C, Serody JS, Blazar BR, Sayers TJ, Murphy WJ (2004) Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 101:8120–8125

    Article  PubMed  CAS  Google Scholar 

  • van de Donk NW, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM (2006) Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 37:1135–1141

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This review was supported by the Swedish Cancer Fund and the Cancer Society of Stockholm.

Author information

Authors and Affiliations

  1. Department of Medicine, Karolinska Institutet and Karolinska University Hospital Huddinge, SE-141 86, Stockholm, Sweden

    Gösta Gahrton

Authors
  1. Gösta Gahrton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gösta Gahrton .

Editor information

Editors and Affiliations

  1. Medizinische Klinik und Poliklinik, Abt. Hämatologie, Onkologie und, Universitätsklinikum Heidelberg, Hospitalstr. 3, Heidelberg, 69115, Germany

    Thomas Moehler

  2. Medizinische Klinik und Poliklinik, Abt. Innere Medizin V, Universitätsklinikum Heidelberg, Hospitalstr. 3, Heidelberg, 69115, Germany

    Hartmut Goldschmidt

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Gahrton, G. (2011). Allogeneic Transplantation in Multiple Myeloma. In: Moehler, T., Goldschmidt, H. (eds) Multiple Myeloma. Recent Results in Cancer Research, vol 183. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-85772-3_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-85772-3_12

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-85771-6

  • Online ISBN: 978-3-540-85772-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation